contrast, in acute lymphoblastic leukaemia (ALL) the risk of leucostasis is less pronounced whereas tumour lysis syndrome is more frequent than in AML (Lowe et al, 2005) .
It has been a matter of continuous debate whether cytoreductive measures, such as leukapheresis (LP) or exchange transfusion (ET) and/or low-dose chemotherapy, before starting full AML therapy are beneficial for patients with HL. Different studies in both adults and children have reached divergent conclusions (Bug et al, 2007; Sung et al, 2012; Oberoi et al, 2014; Creutzig et al, 2016) . A recent paediatric study concluded recommending LP/ET in all cases with WBC >200 9 10 9 /l and for French-American-British (FAB) type M5 cases with WBC >100 9 10 9 /l (Creutzig et al, 2016) .
The Nordic Society of Paediatric Haematology and Oncology (NOPHO) has been registering children with AML up to 15 years in a population-based database since 1984, with patients treated according to five consecutive protocols. Experiences with early morbidity and mortality during the first three protocols have been published previously (Molgaard-Hansen et al, 2010) . One of the findings was that early death was associated with very high WBC, while patients with WBC between 100 and 200 9 109/l did far better. The Nordic population-based registries enable us to study HL in all patients with AML, including those that never started on protocol therapy due to very early fatal complications. Thus, the aim of the present paper was to investigate HL in an unselected, historical patient material, with special emphasis on very high counts (WBC >200 9 10 9 /l). Additional aims were to determine whether the general improvement of outcome in later treatment periods also was true for patients with HL, as well as to contribute further data to the discussion on the potential benefit of LP or ET.
Material and methods

Patients and AML treatment
This study is based on patients aged 0-18 years diagnosed with AML between 1984 and 2014 in the Nordic countries (Denmark, Finland, Sweden, Norway and Iceland) and Hong Kong (from 2007) and registered in the NOPHO database. Data are considered population-based for patients younger than 15 years of age, whereas patients aged 15-18 years are registered according to local practice. Patients with Down syndrome, myelodysplastic syndrome, acute promyelocytic leukaemia, myeloid sarcomas without bone marrow involvement and secondary AML were excluded. Data were collected first by using information reported in the database, followed by questionnaires to the treating hospitals, focusing on additional information on patients with HL, such as cytoreductive measures, symptoms at presentation, extramedullary disease, duration of symptoms before admission to hospital, distance from home to local hospital and from local hospital to paediatric oncology unit.Patients were treated on five consecutive protocols (NOPHO-AML -84, -88, -93, 2004, and NOPHO-DBH AML 2012) 
Treatment of HL
All protocols recommended hydration with continuous intravenous fluids with or without allopurinol (or later rasburicase) and stabilizing the patient before start of the first induction course. A cytoreductive pre-phase with low dose cytarabine was optional but "should be considered". Protocols NOPHO-AML 2004 and NOPHO-DBH AML 2012 contained specific guidelines regarding LP and ET. In the 2004 protocol, a WBC of 100-300 9 10 9 /l was considered as a relative indication for LP/ET, while WBC of 300 9 10 9 /l or above implied a very strong indication. The most recent protocol NOPHO-DBH AML 2012 (NCT01828489) states, "there is no proven benefit of performing either LP or partial ET". We have data on LP/ET in most patients with HL. Data on cytoreduction with low dose chemotherapy was uncertain or missing in many cases, and is reported only in patients who died during the first 2 weeks.
Definitions
HL was defined as an initial WBC of ≥100 9 10 9 /l, and was further subdivided into WBC groups100 to <200 and ≥200 9 10 9 /l. Primary event status was defined as either continuous complete remission, induction death (death within 42 days), resistant disease, relapse, death in complete remission or secondary malignant neoplasm. Early death was defined as death within 14 days from diagnosis, and was subdivided into death within 7 and 14 days. Cause of death was based on clinical findings and, in some cases, autopsy.
Statistics
Statistical analysis was performed using SPSS statistics version 21 (IBM Corp., Armonk, NY). For categorical data, we used the Fisher's exact test or the chi-square test as appropriate to compare the frequency of events. Continuous data were compared using the Student's t-test or Mann Whitney U test, as appropriate. Probability of event-free survival (pEFS) and overall survival (pOS) were calculated using the Kaplan Meier method. EFS was defined as time elapsed between diagnosis and date of induction death, resistant disease (event date set as diagnosis date), relapse, death in complete remission or diagnosis of secondary malignant neoplasm, whichever occurred first. OS was defined as time elapsed between date of diagnosis and death. All living patients were censored at time of last follow-up but not later than 30 April 2016. The log rank test was used to compare survival of subgroups. All tests were two-sided and P-values <0Á05 were considered significant.
Results
In total, data of 890 patients aged 0-18 years, diagnosed with AML between 1984 and 2014 in the Nordic countries and between 2007 and 2014 in Hong Kong were included in the study. Of these, 747 (84%) had a WBC of <100 9 10 9 /l, 86
(10%) had a WBC of 100 to <200 9 10 9 /l and 57 (6%) had a WBC of ≥200 9 10 9 /l (Table I ). There were no significant differences between patients in the three WBC categories regarding sex distribution, country in which they were treated or treatment period ( 
Clinical findings, FAB type and cytogenetics
Patients with HL had significantly more often hepatomegaly, splenomegaly and central nervous system involvement (Table I) . They had a lower frequency of FAB type M2 (14/ 138 = 10% vs. 209/700 = 30%, P < 0Á001), but a higher proportion of FAB type M4/M5 (87/138 = 68% vs. 276/ 700 = 40%, P < 0Á001). RUNX1/RUNX1T1 (t(8;21)) was much less common in patients with WBC ≥100 9 10 9 /l than in those with lower WBC (1/136 = 1% vs. 89/713 = 12%, P < 0Á001), while FLT3-internal tandem duplication (ITD) occurred more frequently (12/57 = 22% vs. 31/325 = 10%, P = 0Á011). In patients with WBC ≥200 9 10 9 /l, KMT2A (also termed MLLT3; t(9;11)) was significantly more frequent (10/52 = 19% vs. 65/ 788 = 8%, P = 0Á007), whereas trisomy 8 was rare (1/52 (2%) vs. 96/745 (13%), P = 0Á019).
Events, survival and death within 14 days
The 10-year pEFS and pOS for all 890 patients was 46 AE 2% and 59 AE 2% respectively. Both pEFS and pOS improved significantly, from 42 AE 2% and 53 AE 2% in time period 1 to 47 AE 3% and 69 AE 3% in time period 2 (P = 0Á03 and <0Á001).
Patients with HL had significantly lower pEFS ( Fig 1A) . Patients with WBC ≥200 9 10 9 /l had significantly more events than all others (74% vs. 54%, P < 0Á01), the most frequent event being induction death (Table I) . Excluding patients with early death during the first week from analysis, pEFS did not differ between patients with HL and patients with WBC <100 9 10 9 /l ( Fig 1C) .
Also pOS was significantly inferior in patients with HL ( Fig 1B) , but this difference disappeared when excluding patients who died within the first 7 days from diagnosis ( Fig 1D) . Survival was nearly identical for WBC <100 and 100 to <200 9 10 9 /l, but significantly inferior for patients with WBC ≥200 9 10 9 /l (39 AE 7% vs. 61 AE 2% for all others, P > 0Á001). Figure 2 shows overall survival for the three WBC categories in two consecutive time periods.
Patients with WBC ≥200 9 10 9 /l had a poor prognosis in both time periods. Overall survival improved significantly from the early to the later time period for patients with WBC <100 9 10 9 /l (54 AE 2% vs. 72 AE 3%, P < 0Á001), but not for patients with WBC 100 to <200 9 10 9 /l (58 AE 7%
vs. 61 AE 8%, log rank 0Á731) or patients with WBC ≥200 9 10 9 /l (30 AE 8% vs. 48 AE 10%, log rank 0Á152). Death during the first 2 weeks from diagnosis was much more frequent in patients with WBC ≥200 9 10 9 /l (17/57, 30%) than in patients with lower WBC (10/833, 1%, P < 0Á001). Patients with WBC ≥200 9 10 9 /l who died within 14 days are listed in Table II . Only a small proportion of these patients (2/17) started the first induction course, both on day 1. Of the 17 patients who died with WBC ≥200 9 10 9 /l, 13 (76%) had WBC above 300 9 10 9 /l, 13 (76%) had FAB type M4 or M5, and 7/14 (50%) had KMT/ MLL aberrations. Sixteen (94%) died within the first week, five of who expired on the day of diagnosis. Two patients received combined low dose chemotherapy and LP and one underwent ET.
Management preceding start of induction course one
Of the total 890 patients included in the study, 20 did not start protocol therapy (induction course 1). Nineteen of these (95%) had HL and all died within the first 2 weeks. 15/19 (79%) had a WBC ≥200 9 10 9 /l. In patients with WBC ≥200 9 10 9 /l cytoreductive therapy with low dose cytarabine was applied in 21/55 (38%). The fraction of patients receiving cytarabine was not significantly different between the first and second time period. Of the 10 patients who died within the first 2 weeks (but after the day of diagnosis) and had complete data, only three (30%) received low-dose cytarabine, none of who started induction therapy. Of the 40 patients surviving the first 2 weeks, 18 (45%) received low dose cytarabine before starting full AML therapy (P = 0Á390). For 41 patients with WBC ≥200 9 10 9 /l who were started on induction course one and had complete data, median interval from diagnosis to start of therapy was 2 (0-12) days. This interval was longer for patients receiving pre-treatment with cytarabine compared to those without pre-treatment (mean 4Á3 vs. 2Á1 days, P = 0Á02).
Of the 135 patients with HL and complete data, LP was performed in seven patients (5%) and ET in 11 patients (8%). Mean WBC for patients with or without LP/ET was 303 AE 132 and 213 AE 129 9 10 9 /l (P = 0Á465). LP or ET was performed in 13/55 (24%) of patients with WBC ≥200 9 10 9 /l and in 5/79 (6%) of patients with WBC 100 to <200 9 10 9 /l. There was no impact of LP or ET on overall survival (pOS with LP/ET: 56 AE 11% vs. without LP/ET 53 AE 5%, P = 0Á575) or frequency of death within the first week (3/15 (20%) with LP/ET, 12/84 (14%) without LP/ET, P = 0Á570).
Distances and time from home to hospital
For patients with HL, median time interval from onset of symptoms to admission was two (0-10) weeks. Median distance from home to the local paediatric hospital was 26 (0-326) km, and from the local hospital to the paediatric CNS, central nervous system; CR1, first complete remission; EMD, extra medullary disease; ET, exchange transfusion; FAB, French-American-British; ITD, internal tandem duplication; LD-AraC, low dose cytarabine; LP, leukapheresis; ND, no data; pEFS, probability of event-free survival; pOS, probability of overall survival; SMN, second malignant neoplasm; WBC, white blood cell count. *Comparing patients with WBC ≥100 vs. <100 9 10 9 /l. †First induction course never started.
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oncology centre 79 (0-780) km. Median time interval from admission to the paediatric hospital to transfer to the paediatric oncology unit was 0 (0-27) days. Neither distances nor time intervals differed significantly for patients with WBC below or above 200 9 10 9 /l, or for patients who died during the first 2 weeks or not (Table SII) . No association between these parameters and survival was found.
Discussion
In this study of 890 children and adolescents with AML, 10% had WBC 100 to <200 9 10 9 /l and 6% had WBC ≥200 9 10 9 /l. Besides confirming known features of HL in paediatric AML, such as over-representation of infants, higher frequency of KMT2A rearrangement, FLT3-ITD and FAB type M4/M5, lower frequency of RUNX1/RUNX1T1 translocation and FAB type M2, we demonstrate that the group with very high WBC (≥200 9 10 9 /l) had a higher incidence of KMT2A/AFF1 and reduced frequency of trisomy 8. In our experience, the WBC group ≥100 to <200 9 10 9 /l does not stand out as a particularly poor prognostic group, whereas patients with WBC ≥200 9 10 9 /l had a significantly inferior prognosis, due to their high frequency of deaths within the first 2 weeks (30% vs. 1% for all others). The study revealed that 26% of patients with HL never received the first protocol induction course, and that treatment results have not improved significantly during the last three decades. This study has some limitations, mainly related to the retrospective design covering a long time span. Some of the data is uncertain due to missing or unclear reporting, particularly for the early patients before 1993 (first two NOPHO studies). Cause of death was most often based on clinical findings without autopsy. In patients reported as "No treatment" it was often uncertain if they had received low-dose chemotherapy while trying to stabilize the patient. Even if this is one of the largest studies on paediatric HL in AML, The strength of the study lies in the population-based registration for patients younger than 15 years, where all patients with an AML diagnosis are registered. Thus, we could include even some patients who died at admittance where the AML diagnosis was established post mortem. Further, the long time span allowed us to evaluate development over time, including recommendations for management of HL as well as the impact of consecutive protocols.
We were not able to demonstrate a significant improvement of outcome for patients with HL from the early to the later period. However, survival in the WBC group 100 to <200 9 10 9 /l was quite favourable already in the first period (58%). For the WBC group ≥200 9 10 9 /l, we found a trend towards improved survival (48% in the second period compared to 30% in the first period), which did not reach statistical significance due to the small numbers. At least two international groups have reported significant improvements of outcome in patients with HL in recent years due to reduction of early deaths (Creutzig et al, 2004; Inaba et al, 2008) . The Berlin-Frankfurt-M€ unster (BFM) group (Creutzig et al, 2004) reported that significantly fewer patients died within the first 6 weeks in the most recent treatment protocol, but not all of these patients had HL. The authors discussed possible reasons and emphasized that children with AML should be treated exclusively at specialized large paediatric cancer centres. The study reported by Inaba et al (2008) was conducted at a single large centre specialized in the care of paediatric cancer patients. The rate of early death was significantly higher in the early period than in the late period. However, overall survival for patients without HL in the most recent time period was only 43 AE 3%, which is in the same range as for the patients with HL in our study. In the Nordic countries with scarce population and, often, long distances to specialized centres, AML patients often have to be handled initially at small departments. However, we were not able to demonstrate an association between early death rate and distance from home to hospital or from primary hospital to the oncology centre. It is known that the risk of early morbidity and mortality is correlated to increasing WBC (Inaba et al, 2008; Sung et al, 2012) . We found that the WBC category ≥200 9 10 9 /l stands out as a particularly poor risk group, with an early death rate of 30%, which is higher than reported from the BFM group (Creutzig et al, 2004) and The Children's Oncology Group (COG) (Sung et al, 2012) . The BFM group reported an early death rate (<14 days) of 17% for patients with WBC above 200 9 10 9 /l. The study included patients diagnosed between 1993 and 2002, including FAB type M3 (Creutzig et al, 2004) . The COG study had an induction I death frequency of 1Á5/8Á0/10Á5% for WBC of 200 to <300/ 300 to <400/≥400 9 10 9 /l (Sung et al, 2012) (corresponding figures in our study for death within 2 weeks were 17/33/ 44%). Of note, median time to death was 19Á5 and 4Á5 days in the two highest WBC groups (Sung et al, 2012) . The poor survival in our study in patients with WBC ≥200 9 10 9 /l is almost entirely due to the high early death rate. Having survived the first 2 weeks, these patients had a similar survival to those patients with lower WBC. Most of the patients who died in the first 2 weeks had WBC ≥300 9 10 9 /l, which means that treatment recommendations mainly have to focus on that group. Most of the 21 patients with HL who died within the first 2 weeks did so without commencing intensive AML chemotherapy, i.e. the first induction course. This is readily explicable for the five patients dying of intracranial haemorrhage or anaesthesia-related complications on day one, but in most patients reflects a time interval used for stabilizing the patients with or without attempting to lower the WBC. A common advice in the literature has been to stabilize patients with HL, including measures to lower the initial WBC before starting AML chemotherapy (Inaba et al, 2008) . Others have emphasized the importance of starting antileukaemic therapy early (Chang et al, 2007; Chen et al, 2014) . The benefit of invasive measures (LP or ET) is still debated in adult (Giles et al, 2001; Bug et al, 2007; Chang et al, 2007; Marbello et al, 2008; Oberoi et al, 2014; Pastore et al, 2014) and paediatric AML (Sung et al, 2012; Creutzig et al, 2016) . Some of the major objections are that LP and ET may delay chemotherapy, and that most complications are observed at presentation before LP/ET can be initiated, and thus are not preventable by cytoreduction (Lowe et al, 2005) . The procedures also carry a risk related to the insertion of a central venous line in critically ill patients, and they may have limited efficacy in patients with massive organomegaly (Lowe et al, 2005) . Retrospective studies are biased in several ways, given that patients with very high WBC and complications may be elected for LP/ET more often (potential lower survival in the LP/ET group), but also that patients may have died before being considered for invasive cytoreduction (potential lower survival in patients treated without LP/ET). There are several studies reporting a low frequency of complications of LP and ET in children (Haase et al, 2009; Greze et al, 2014) . However, in a recent study on paediatric ALL and AML, Abla et al (2016) reported a higher frequency of complications in patients who underwent leukapheresis. The COG study (Sung et al, 2012) concluded that leukapheresis does not reduce induction mortality. In contrast, a recent paper from the BFM Group reported a trend towards better outcome in patients undergoing LP/ET and advocated LP/ET mainly in patients with WBC >200 9 10 9 /l and in subgroups of patients with lower WBC (Creutzig et al, 2016) . Others have recommended very early start of antileukaemic treatment as an adequate measure to control early morbidity and mortality (Chang et al, 2007; Chen et al, 2014) . Chen et al (2014) treated 17 children with AML and HL with prompt chemotherapy without LP and registered only one early death.
The numbers in our study are too small to make reliable statements about the benefit of cytoreductive measures by low dose cytarabine or LP/ET. However, we interpret the fact that patients with WBC of 100 to <200 9 10 9 /l had a similar survival as patients with lower WBC -and only 5 of 79 of these patients underwent LP or ET -to support not recommending LP/ET in this WBC group. We conclude that the inferior survival for patients with HL in our study can be attributed to the high frequency of early deaths within the first week of diagnosis. Measures to improve results have to focus on the first days of management. The NOPHO AML group acknowledges that unequivocal conclusions about the potential benefit of LP/ET will not be available in the near future. At present we do not believe that there is convincing evidence to recommend LP/ET even in patients with WBC ≥200 9 10 9 /l. Within the NOPHO-AML group we advocate rapid initiation of intensive chemotherapy, preferably within a few hours after confirming an AML diagnosis, together with immediate correction of coagulation abnormalities, administration of rasburicase and maintenance of a high urinary output. All diagnostics can be made from peripheral blood and invasive diagnostic measures and general anaesthesia may be avoided in unstable patients.
